Literature DB >> 15310308

Relation between serum Insulin-like growth factor-I and insulin-like growth factor-binding protein-3 levels, clinical status and growth parameters in prepubertal cystic fibrosis patients.

Metehan Ozen1, Haluk Cokugras, Naile Ozen, Yildiz Camcioglu, Necla Akcakaya.   

Abstract

BACKGROUND: This study aims to determine the relation between anabolic hormones, Insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3), growth parameters, and clinical status in prepubertal cystic fibrosis (CF) patients. This prospective study comprises age/sex-matched control subjects and was set in a tertiary care teaching hospital.
METHODS: Serum concentrations of IGF-I and IGFBP-3 were measured in 37 CF and 23 healthy subjects, whose mean ages were 5.02 +/- 3.06 and 5.27 +/- 2.82, respectively. The results were analyzed in relation to body mass index standard deviation scores (BMISD), height standard deviation scores (HSD), growth velocity standard deviation scores (GVSD), and clinical status assessed by Shwachman scores and pulmonary function parameters.
RESULTS: Serum IGFBP-3 of CF patients showed significantly lower concentrations than healthy subjects (2457 vs. 3249 ng/mL) (P < 0.05), whereas IGF-I levels did not (123.35 vs. 149.8 ng/mL). There was significant positive correlation between IGF-I and IGFBP-3 with HSD (r = 0.62; r = 0.79) and BMISD (r = 0.39; r = 0.50). The pulmonary function tests in 14 CF subjects were not statistically worse than in nine healthy cases. The mean HSD (-0.67, SD 1.06) and BMISD (-0.28, SD 0.71) of CF patients were not significantly lower than those of healthy subjects (-0.02, SD 0.86 and 0.03, SD 0.49), respectively.
CONCLUSION: Decreased serum IGF-I and IGFBP-3 levels may reflect growth retardation in CF. IGFBP-3 seems like a more sensitive parameter than IGF-I for growth monitoring in this study. Growth parameters of Turkish prepubertal CF patients are not markedly below national standards. Different genetic backgrounds of relevant populations certainly play an important role for the variable clinical course.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15310308     DOI: 10.1111/j.1442-200x.2004.01925.x

Source DB:  PubMed          Journal:  Pediatr Int        ISSN: 1328-8067            Impact factor:   1.524


  9 in total

1.  Role of IGF-I, IGF-II and IGFBP-3 in lung function of males: the Caerphilly Prospective Study.

Authors:  Christopher J Green; Jeffrey M Holly; Charlotte E Bolton; Antony Bayer; Shah Ebrahim; John Gallacher; Yoav Ben-Shlomo
Journal:  Int J Mol Epidemiol Genet       Date:  2014-05-29

2.  Estrogen sulfotransferase in the metabolism of estrogenic drugs and in the pathogenesis of diseases.

Authors:  Anne Caroline S Barbosa; Ye Feng; Chaohui Yu; Min Huang; Wen Xie
Journal:  Expert Opin Drug Metab Toxicol       Date:  2019-03-18       Impact factor: 4.481

3.  Insulin-like growth factor-binding protein-3 (IGFBP-3) blocks the effects of asthma by negatively regulating NF-κB signaling through IGFBP-3R-mediated activation of caspases.

Authors:  Yong-Chul Lee; Sherryline Jogie-Brahim; Dae-Yeol Lee; Jinfeng Han; Aki Harada; Liam J Murphy; Youngman Oh
Journal:  J Biol Chem       Date:  2011-03-07       Impact factor: 5.157

4.  Respiratory epithelial gene expression in patients with mild and severe cystic fibrosis lung disease.

Authors:  Jerry M Wright; Christian A Merlo; Jeffrey B Reynolds; Pamela L Zeitlin; Joe G N Garcia; William B Guggino; Michael P Boyle
Journal:  Am J Respir Cell Mol Biol       Date:  2006-04-13       Impact factor: 6.914

5.  Serum insulin-like growth factor-1 (IGF-1) during CF pulmonary exacerbation: trends and biomarker correlations.

Authors:  A H Gifford; A B Nymon; A Ashare
Journal:  Pediatr Pulmonol       Date:  2013-06-18

6.  Increased SULT1E1 activity in HepG2 hepatocytes decreases growth hormone stimulation of STAT5b phosphorylation.

Authors:  Li Li; Dongning He; Teresa W Wilborn; Josie L Falany; Charles N Falany
Journal:  Steroids       Date:  2008-09-11       Impact factor: 2.668

7.  Low levels of insulin-like growth factor-1 contribute to alveolar macrophage dysfunction in cystic fibrosis.

Authors:  Jamie L Bessich; Amanda B Nymon; Lisa A Moulton; Dana Dorman; Alix Ashare
Journal:  J Immunol       Date:  2013-05-22       Impact factor: 5.422

Review 8.  The insulin-like growth factor system and nutritional assessment.

Authors:  Callum Livingstone
Journal:  Scientifica (Cairo)       Date:  2012-07-08

Review 9.  Insulin-Like Growth Factor-1 Signaling in Lung Development and Inflammatory Lung Diseases.

Authors:  Zheng Wang; Wenting Li; Qiongya Guo; Yuming Wang; Lijun Ma; Xiaoju Zhang
Journal:  Biomed Res Int       Date:  2018-06-19       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.